DOLAF- An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib
Séverine Guiu, MD, PhD (ICM-Institut du Cancer de Montpellier)
Judith Balmaña, MD, PhD (Vall d'Hebron Institute of Oncology, Barcelona)
Philippe Follana, MD (Centre Antoine Lacassagne)